Ninds drug manufacturing and formulation program (DMFP)

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N98026D00014
Awardee
Awarding agency
Task orders
1 $1,363,408 obligated

Award facts

Opportunity
Combined order value
  • $1,363,408 Current, with exercised options
  • $2,534,752 Potential, with all options
Last date to order 5% complete
IDV ceiling 3% used
$49,999,999.00
Award type
Multiple award
Who can order
Only the awarding agency
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 7 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute of Neurological Disorders and Stroke awarded an indefinite-delivery contract to Mriglobal for drug manufacturing and formulation services under the Drug Manufacturing and Formulation Program (DMFP), a multiple-award vehicle with a $49,999,999 ceiling and an award date of May 4, 2026.

No set-aside applies. Place of performance is Kansas City, Missouri, with subordinate laboratory and pharmaceutical manufacturing facilities across multiple locations including the headquarters facility housing 60,000 square feet of dedicated laboratory space.

The solicitation, posted May 3, 2024, sought contractors capable of performing API scale-up and manufacturing, formulation and dosage form manufacturing, analytical methods development, and stability testing to enable candidate molecules in the Blueprint Neurotherapeutics Network to enter clinical-stage development. The opportunity anticipated multiple awards with a ten-year ordering period and task order requests for each DMFP project. Full and open competition applied, with no set-aside.

The period of performance runs through May 3, 2036, with a base plus options structure. NAICS code 325412 (Pharmaceutical Preparation Manufacturing) is applicable.

As of August 15, 2026, NINDS issued a delivery order to Mriglobal valued at $2,534,752 for manufacturing of a selective CB2 agonist, with place of performance in Kansas City, Missouri and performance completion through August 14, 2032. The order carries cost-plus-fixed-fee pricing.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N98026D00014?

75N98026D00014 was awarded to Mriglobal by Office of Logisitics and Acquisition Operations (National Institutes of Health) on May 4, 2026.

How much is contract 75N98026D00014 worth?

Orders under 75N98026D00014 have obligated $1,363,408. Their combined potential value, with all options, is $2,534,752. 75N98026D00014's own ceiling is $49,999,999.

How many orders have been placed under contract 75N98026D00014?

1 order has been placed under 75N98026D00014, the latest on August 15, 2026.

Which agency awarded contract 75N98026D00014?

Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026D00014, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

Who can order from contract 75N98026D00014?

75N98026D00014 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N98026D00014 competed?

The extent of competition for 75N98026D00014 was full and open competition. The government received 7 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV